Amritsar Online

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

 Breaking News
  • No posts were found

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

July 31
14:21 2020
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Delveinsight Business Research
DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease (ADPKD), historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder which causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure. 

ADPKD may lead to development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRP). The most common extrarenal manifestation is olycystic liver disease (PLD), which is more common in women than in men.  Genetic mutation plays a major role in the pathogenesis of ADPKD, mainly mutations in the PKD1, PKD2 genes leads to cyst formation and its progressive growth. 

 

Get FREE sample copy at: 

https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market

 autosomal-dominant-polycystic-kidney-disease-ADPKD-market

The Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report also covers emerging drugs, current treatment practices, Autosomal Dominant Polycystic Kidney Disease (ADPKD) market share of the individual therapies, current and forecasted Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

 

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Key Facts

ADPKD affects nearly 12.4 million people worldwide. About nine out of every 10 people with PKD have the autosomal dominant form.

The prevalence of ADPKD is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year (Rashid, 2018).

About 1 in 2 people with ADPKD develop kidney failure by the age of 60 and will need dialysis or a kidney transplant.

The United States has the highest percentage of diagnosed & treated patients of ADPKD in the 7MM.

 

Key Benefits of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Report

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report provides an in-depth analysis of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report will help in developing business strategies by understanding the Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market trends & developments, key players and future market competition that will shape and drive the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market in the upcoming years.

  • The Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report covers Autosomal Dominant Polycystic Kidney Disease (ADPKD) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market

There is no cure for ADPKD and it is not possible to stop cysts forming in the kidneys, however, a lot of research has been done in this space to find ways to manage the disease. The progressiveness of this disease and its complications cause debilitating effects on the health of patients and impose a significant burden, both economically and on the quality of life. The majority of patients with ADPKD will eventually develop ESRD and require RRT

 The Autosomal Dominant Polycystic Kidney Disease (ADPKD) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Autosomal Dominant Polycystic Kidney Disease (ADPKD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Autosomal Dominant Polycystic Kidney Disease (ADPKD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Epidemiology

As per the DelveInsight’s Analysis, it is observed that diagnosis of ADPKD is high in the 7MM, and similarly, a high rate of treatment is seen in diagnosed cases of ADPKD patients. The therapies under development are focused on novel approaches to treat/improve the disease condition and the research over the past decade suggests that it is possible to target the mechanism that triggers the growth of cysts in the first place.

 The Autosomal Dominant Polycystic Kidney Disease (ADPKD) epidemiology section covers insights about historical and current Autosomal Dominant Polycystic Kidney Disease (ADPKD) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs Uptake and Key Market Players

The Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market or expected to get launched in the market during the study period. The analysis covers Autosomal Dominant Polycystic Kidney Disease (ADPKD) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Some of the key Pharma companies are involved in the development of therapies for the treatment of ADPKD patients. Owing to the launch of these emerging therapies, the market scenario of ADPKD may significantly impacted in the coming years 2020–2030..

The Key players in the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market includes:
Kyowa Hakko Kirin
Palladio Biosciences
Sanofi
Reata Pharmaceuticals
Regulus Therapeutics
And may others

Drugs covered.
Venglustat
Bardoxolone
Lixivaptan
RGLS4326
XRx-008
And others

 

Table of Content

1. Key Insights

2. Executive Summary 

3. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Competitive Intelligence Analysis

4. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Overview at a Glance

5. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Disease Background and Overview

6. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patient Journey

7. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Epidemiology and Patient Population

8. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Treatment Algorithm, Current Treatment, and Medical Practices

9. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Unmet Needs

10. Key Endpoints of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Treatment

11. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Marketed Products

12. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Emerging Therapies

13. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Seven Major Market Analysis

14. Attribute Analysis

15. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Outlook (7 major markets)

16. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Access and Reimbursement Overview

17. KOL Views on the Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market.

18. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Drivers

19. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

Related Reports

Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast to 2030

DelveInsight’s Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Autosomal Dominant Polycystic Kidney Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Autosomal Dominant Polycystic Kidney Disease Pipeline Insights, 2020

Autosomal Dominant Polycystic Kidney Disease Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Autosomal Dominant Polycystic Kidney Disease market.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles